Moderna, Inc. (MUN:0QF)
| Market Cap | 11.52B |
| Revenue (ttm) | 1.90B |
| Net Income (ttm) | -2.66B |
| Shares Out | n/a |
| EPS (ttm) | -6.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12 |
| Average Volume | 181 |
| Open | 26.28 |
| Previous Close | 25.40 |
| Day's Range | 26.28 - 27.02 |
| 52-Week Range | 20.18 - 46.34 |
| Beta | n/a |
| RSI | 59.53 |
| Earnings Date | Feb 20, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Noteworthy ETF Inflows: XBI, FOLD, MRNA, EXEL
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approxima...
Forget Moderna Stock, This is a Much Better Buy
This stock is a great choice for cautious and aggressive investors.
Moderna Stock Sees Healthy Relative Strength Rating
Moderna shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Moderna: On Transition From Pandemic Windfall To Multi-Product Platform, Initiating At Neutral
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
The latest trading day saw Moderna (MRNA) settling at $32.29, representing a -7.48% change from its previous close.
Moderna: Why I Am Selling The 'Relief Rally'
Rivian, Sandisk, And Moderna Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio ? Rivian Automotive, Inc. (NASDAQ: RIVN) gained 20.57% this week afterthe company said it is expanding hand...
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
Down 80%, Should You Buy the Dip on Moderna?
Moderna's earnings and stock price climbed during early pandemic days -- that's as demand for the company's coronavirus vaccine soared. Since, the company has faced various challenges that have weighe...
Noteworthy Thursday Option Activity: AVGO, MRNA, IBM
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Broadcom Inc (Symbol: AVGO), where a total volume of 357,843 contracts has been traded ...
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback
Moderna (MRNA) Secures $54.3M Funding for Bird Flu Vaccine Trial
Moderna (MRNA) Secures $54.3M Funding for Bird Flu Vaccine Trial
Moderna (MRNA) Advances with $54.3M Boost for H5 Flu Vaccine Trials
Moderna (MRNA) Advances with $54.3M Boost for H5 Flu Vaccine Trials
Moderna granted up to $54.3M from CEPI for bird flu vaccine
Moderna secures up to US$54.3 million funding for bird flu vaccine from global coalition
Moderna will get up to US$54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday
Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition
Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.
Moderna, Inc.: CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensurePartnership strengthens global preparedness against a significant pandemic thr...
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensurePartnership strengthens global preparedness against a significant pandemic threat...
Moderna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts
Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the fun...
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threa...
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth
Moderna, Inc.: Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:3...
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p...
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p...